Avinger competitors

Mr. Ward has been a member of our Board of Directors since 2013 and has served as Chairman since November 2014. Mr. Ward served as our Interim President and Chief Executive Officer commencing in November 2015. In August 2016, Mr. Ward was appointed President and Chief Executive Officer. Since 2013, Mr. Ward has been one of the Managing Directors at SightLine Partners. Following his appointment as our President and Chief Executive Officer, Mr. Ward continues to be a Managing Director of Sightline Opportunity Management Fund II, LLC, and may provide limited advisory and consulting services to Sightline Partners in this capacity.

George Lemaitre is a Chairman/CEO at LEMAITRE VASCULAR INC, Manager at Lemaitre Family LLC, and Board Member at VASCUTECH INC and is based in Greater Boston Area. He has worked as Board Member at LEMAITRE VASCULAR INC, Credit Analyst at Connecticut National Bank/Bridgeport CT, and Associate at MCCOWN DE LEEUW & CO. George works or has worked as Board of Directors at LEMAITRE VASCULAR INC, Owner at LEMAITRE VASCULAR INC, and BOARD MEMBER at Stanford Univ Graduate Schl of Bussiness Management. He attended Stanford Graduate School of Business between 1990 and 1992, Phillips Academy Andover between 1978 and 1982, and Stanford University between 1982 and 1986.

Scott Huennekens has served as President and Chief Executive Officer since April 2002. From January 2000 to March 2002, he served as the President and Chief Executive Officer of Digirad Corporation, a medical imaging company. Mr. Huennekens is a member of the Board of Directors for Volcano Corporation, Uptake Medical, the Medical Device Manufacturers Association (MDMA), and BIOCOM. He received a B.S. in Business Administration from the University of Southern California and an M.B.A. from Harvard Business School.

Bruce Shook is a medical device executive with more than 30 years of industry experience, including multiple early stage ventures focused on opportunities in cardiac surgery, cardiology, neurosurgery, psychiatry and vascular disease. He serves as Director, President and CEO for both Intact Vascular and Vesper Medical. Intact Vascular is a privately held medical technology company that develops and commercializes vascular scaffolding technology for the treatment of peripheral arterial disease. The company is currently marketing the Tack Endovascular System® in the U.S. and Europe. Vesper Medical was spun out of Intact Vascular in late 2016 and is developing a novel family of venous stents designed to treat deep venous disease. Prior to Intact Vascular and Vesper Medical, Mr. Shook was co-founder, Director, President and CEO of Neuronetics, Inc., [NASDAQ: STIM] a publicly traded device company that markets a non-invasive brain stimulation technology for the treatment of depression. Previously, Mr. Shook was co-founder, Director, President and CEO at Neuron Therapeutics, a venture-backed company developing a drug/device product for the treatment of CNS disorders, and President of Abiomed [NASDAQ: ABMD], where he obtained PMA approval for the first FDA-approved ventricular assist device. Mr. Shook also developed cardiac pacing and anti-arrhythmia products at Cordis Corporation. Mr. Shook holds advanced degrees in Biomedical Engineering and Business Administration from Columbia University and the MIT Sloan School of Management, respectively. He earned a B.S. degree in Chemical Engineering from Penn State University. Mr. Shook currently serves on the Board of Directors at Neuronetics, Venarum Medical, the Penn State Research Foundation (Vice Chairman) and Life Sciences Pennsylvania (Medical Technology Committee Chairman). He previously served on the Board of Directors at Surgiquest, Respicardia and CoTherix.

Greg Sullivan, Founder and CEO, leads the MMS management team. Mr. Sullivan has extensive experience in the Medical Device Industry with over 25 years in the minimally invasive neurology and cardiology market. His extensive experience combines a traditional corporate background with leadership roles in several emerging technology medical device companies. He has been involved in the successful launch of over 25 products in the endovascular, interventional cardiology, interventional neurology and ENT markets. His leadership has taken these devices from development to building innovative minimally invasive technology through demonstrated clinical outcomes, to acquisition and sale of a mature organization. Mr. Sullivan has held Senior Management positions for both public and venture backed private companies. He has served in progressively responsible roles for Arterial Vascular Engineering (acquired by Medtronic, 1998, $4.3 billion), Precision Vascular Solutions (acquired by Boston Scientific, 2002, $80 million), Acclarent, Inc. (acquired by J&J 2007, $785 million), Chestnut Medical (acquired by EV3/Covidien 2008 $100 million). Several of the products in which he was intimately involved with remain industry leaders to this day.